214 related articles for article (PubMed ID: 30539525)
61. Adenovirus-mediated gene transfer of enhanced Herpes simplex virus thymidine kinase mutants improves prodrug-mediated tumor cell killing.
Wiewrodt R; Amin K; Kiefer M; Jovanovic VP; Kapoor V; Force S; Chang M; Lanuti M; Black ME; Kaiser LR; Albelda SM
Cancer Gene Ther; 2003 May; 10(5):353-64. PubMed ID: 12719705
[TBL] [Abstract][Full Text] [Related]
62. Comparison of the effects of three different toxin genes and their levels of expression on cell growth and bystander effect in lung adenocarcinoma.
Hoganson DK; Batra RK; Olsen JC; Boucher RC
Cancer Res; 1996 Mar; 56(6):1315-23. PubMed ID: 8640820
[TBL] [Abstract][Full Text] [Related]
63. Prodrugs in genetic chemoradiotherapy.
Patterson AV; Saunders MP; Greco O
Curr Pharm Des; 2003; 9(26):2131-54. PubMed ID: 14529410
[TBL] [Abstract][Full Text] [Related]
64. Lentiviral HSV-Tk.007-mediated suicide gene therapy is not toxic for normal brain cells.
Hossain JA; Ystaas LR; Mrdalj J; Välk K; Riecken K; Fehse B; Bjerkvig R; Grønli J; Miletic H
J Gene Med; 2016 Sep; 18(9):234-43. PubMed ID: 27490042
[TBL] [Abstract][Full Text] [Related]
65. Bystander effects in enzyme/prodrug gene therapy.
Paillard F
Hum Gene Ther; 1997 Oct; 8(15):1733-5. PubMed ID: 9358021
[No Abstract] [Full Text] [Related]
66. Transfection of oral cancer cells mediated by transferrin-associated lipoplexes: mechanisms of cell death induced by herpes simplex virus thymidine kinase/ganciclovir therapy.
Neves SS; Sarmento-Ribeiro AB; Simões SP; Pedroso de Lima MC
Biochim Biophys Acta; 2006 Nov; 1758(11):1703-12. PubMed ID: 17049485
[TBL] [Abstract][Full Text] [Related]
67. Bystander effects of different enzyme-prodrug systems for cancer gene therapy depend on different pathways for intercellular transfer of toxic metabolites, a factor that will govern clinical choice of appropriate regimes.
Denning C; Pitts JD
Hum Gene Ther; 1997 Oct; 8(15):1825-35. PubMed ID: 9358032
[TBL] [Abstract][Full Text] [Related]
68. Synergy between the herpes simplex virus tk/ganciclovir prodrug suicide system and the topoisomerase I inhibitor topotecan.
Wildner O; Blaese RM; Morris JC
Hum Gene Ther; 1999 Nov; 10(16):2679-87. PubMed ID: 10566896
[TBL] [Abstract][Full Text] [Related]
69. Efficacy of adenovirus-mediated CD/5-FC and HSV-1 thymidine kinase/ganciclovir suicide gene therapies concomitant with p53 gene therapy.
Xie Y; Gilbert JD; Kim JH; Freytag SO
Clin Cancer Res; 1999 Dec; 5(12):4224-32. PubMed ID: 10632364
[TBL] [Abstract][Full Text] [Related]
70. Increased Cytotoxicity of Herpes Simplex Virus Thymidine Kinase Expression in Human Induced Pluripotent Stem Cells.
Iwasawa C; Tamura R; Sugiura Y; Suzuki S; Kuzumaki N; Narita M; Suematsu M; Nakamura M; Yoshida K; Toda M; Okano H; Miyoshi H
Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30769780
[TBL] [Abstract][Full Text] [Related]
71. Use of suicide genes for cancer gene therapy: study of the different approaches.
Vassaux G; Martin-Duque P
Expert Opin Biol Ther; 2004 Apr; 4(4):519-30. PubMed ID: 15102601
[TBL] [Abstract][Full Text] [Related]
72. Highly efficient gene transfer to solid tumors in vivo by tumor-selective replicating retrovirus vectors.
Lu YC; Luo YP; Wang YW; Tai CK
Int J Mol Med; 2010 May; 25(5):769-75. PubMed ID: 20372821
[TBL] [Abstract][Full Text] [Related]
73. Long-circulating liposome-encapsulated ganciclovir enhances the efficacy of HSV-TK suicide gene therapy.
Kajiwara E; Kawano K; Hattori Y; Fukushima M; Hayashi K; Maitani Y
J Control Release; 2007 Jul; 120(1-2):104-10. PubMed ID: 17509714
[TBL] [Abstract][Full Text] [Related]
74. Pharmacological modulation of the bystander effect in the herpes simplex virus thymidine kinase/ganciclovir gene therapy system: effects of dibutyryl adenosine 3',5'-cyclic monophosphate, alpha-glycyrrhetinic acid, and cytosine arabinoside.
Robe PA; Princen F; Martin D; Malgrange B; Stevenaert A; Moonen G; Gielen J; Merville M; Bours V
Biochem Pharmacol; 2000 Jul; 60(2):241-9. PubMed ID: 10825469
[TBL] [Abstract][Full Text] [Related]
75. Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo.
DiMaio JM; Clary BM; Via DF; Coveney E; Pappas TN; Lyerly HK
Surgery; 1994 Aug; 116(2):205-13. PubMed ID: 8047987
[TBL] [Abstract][Full Text] [Related]
76. Suicide gene therapy in liver tumors.
Jiao LR; Havlik R; Nicholls J; Jensen SL; Habib NA
Methods Mol Med; 2004; 90():433-50. PubMed ID: 14657577
[TBL] [Abstract][Full Text] [Related]
77. The role of cellular- and prodrug-associated factors in the bystander effect induced by the Varicella zoster and Herpes simplex viral thymidine kinases in suicide gene therapy.
Grignet-Debrus C; Cool V; Baudson N; Velu T; Calberg-Bacq CM
Cancer Gene Ther; 2000 Nov; 7(11):1456-68. PubMed ID: 11129288
[TBL] [Abstract][Full Text] [Related]
78. Radiosensitization and anti-tumour effects of cytosine deaminase and thymidine kinase fusion suicide gene in human adenoid cystic carcinoma cells.
Huang SY; Zhang DS; Han JQ; Zhang N; Zhang SZ; Mu WL; Wei FC
J Int Med Res; 2009; 37(2):479-90. PubMed ID: 19383243
[TBL] [Abstract][Full Text] [Related]
79. In vivo enhancement of herpes simplex virus thymidine kinase/ganciclovir cancer gene therapy with polyamine biosynthesis inhibition.
Wahlfors T; Hakkarainen T; Jänne J; Alhonen L; Wahlfors J
Int J Cancer; 2006 Jun; 118(11):2907-10. PubMed ID: 16385565
[TBL] [Abstract][Full Text] [Related]
80. A guanylate kinase/HSV-1 thymidine kinase fusion protein enhances prodrug-mediated cell killing.
Willmon CL; Krabbenhoft E; Black ME
Gene Ther; 2006 Sep; 13(17):1309-12. PubMed ID: 16810197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
